Our Horizon Europe Project PragmaTIL made it to World Patient Safety Congress!
During the event, our team was able to talk about the Horizon Europe Project Asphalion is part of.
The PragmaTIL trial aims to optimize treatment of cancer patients with Tumour-Infiltrating Lymphocytes Adoptive Cell Therapy (TIL-ACT) and substantially expand and improve the clinical implementation of this treatment modality in academic hospitals. To this end, treatment related toxicities, associated to high-dose interleukin 2 (HD-IL-2) required for expansion and activation of TILs will be reduced while maintaining efficacy.
This improved tolerability will achieve a better clinical management of patients and enhance their quality of life, both of which represent major barriers for applying this treatment.
If you require any assistance for your Horizon projects, contact us at [email protected]
